Towards optimal cut-off trough levels of adalimumab and etanercept for a good therapeutic response in rheumatoid arthritis. Results of the INMUNOREMAR study

Ann Rheum Dis. 2015 Aug;74(8):e42. doi: 10.1136/annrheumdis-2015-207530. Epub 2015 Mar 24.
No abstract available

Keywords: DAS28; Rheumatoid Arthritis; Treatment.

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies / blood*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antirheumatic Agents / blood*
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / drug therapy*
  • Female
  • Humans
  • Immunoglobulin G / therapeutic use*
  • Male
  • Receptors, Tumor Necrosis Factor / therapeutic use*

Substances

  • Antibodies
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor